CompletedPhase 3

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

United States25 participantsStarted 2003-11

Plain-language summary

This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females at least 18 years of age. * Diagnosis of Zollinger-Ellison Syndrome or idiopathic hypersecretion Exclusion Criteria: * Pregnant or lactating females * History of drug addiction or alcohol abuse within 12 months prior to Screening. * History of intolerance to any proton pump inhibitors or any ingredient in their formulation.

What they're measuring

To assess the gastric acid secretory rate at the final study visit.

Control is defined as gastric acid secretory rate below 10 mEq/h or below 5 meq/h for patients with prior gastric acid reducing Surgery

Trial details

NCT IDNCT00079833

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Zollinger-Ellison Syndrome trials